Do Major Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial Differ by Healthcare System?

Author:

Chaitman Bernard R.1,Hartigan Pamela M.1,Booth David C.1,Teo Koon K.1,Mancini G.B. John1,Kostuk William J.1,Spertus John A.1,Maron David J.1,Dada Marcin1,O'Rourke Robert A.1,Weintraub William S.1,Berman Daniel S.1,Shaw Leslee J.1,Boden William E.1,

Affiliation:

1. From the Department of Internal Medicine (B.R.C.), Saint Louis University School of Medicine, St Louis, Mo; VA Connecticut Healthcare System (P.M.H.), West Haven, Conn; Lexington VA Medical Center (D.C.B.), Lexington, Ky; McMaster University Medical Center (K.K.T.), Hamilton, Ontario, Canada; Department of Medicine (G.B.J.M.), Vancouver Hospital & Health Sciences Center, Vancouver, BC, Canada; London Health Sciences Centre (W.J.K.), London, Ontario, Canada; Mid America Heart Institute/UMKC (J.A...

Abstract

Background— The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial enrolled patients from 3 distinct healthcare systems (HCSs) in North America. The primary aim of this study was to determine whether there is a treatment difference in cardiovascular outcomes by HCS. Methods and Results— The study population included 968 patients from the US Department of Veterans Affairs (VA), 386 from the US non-VA, and 931 from Canada with different comorbidities and prognoses. The primary outcome was all-cause mortality or nonfatal myocardial infarction (MI) during the median 4.6-year follow-up. Baseline demographics were similar between percutaneous coronary intervention and optimal medical therapy treatment groups within each HCS. After follow-up, the primary end point of total mortality and nonfatal MI was not statistically significant between percutaneous coronary intervention and optimal medical therapy, regardless of HCS: VA, 22.3% versus 21.9% (hazard ratio, 1.05; 95% CI, 0.80–1.38; P =0.95); US non-VA, 15.8% versus 21.8% (hazard ratio, 0.70; 95% CI, 0.43–1.12; P =0.24); Canadian HCS, 17.3% versus 13.5% (hazard ratio, 1.30; 95% CI, 0.93–1.83; P =0.17). The interaction between HCSs and treatment was not statistically significant. Long-term mortality was significantly higher in the VA system as a result of significantly greater comorbidity and worse left ventricular function. Conclusions— In the COURAGE trial, addition of percutaneous coronary intervention to optimal medical therapy did not improve 5-year survival or reduce MI or other major adverse cardiovascular events regardless of whether patients were Canadian or American or US veterans or nonveterans. Outcome differences were largely explained by differences in baseline characteristics known to affect long-term prognosis. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00007657.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3